Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-1.57%
$213.70
0% positive prob.
5-Day Prediction
-3.49%
$209.54
0% positive prob.
20-Day Prediction
-3.38%
$209.78
0% positive prob.
SEC 8-K filings with transcript text
Feb 4, 2026 · 100% conf.
1D
-1.57%
$213.70
Act: +0.73%
5D
-3.49%
$209.54
Act: +1.70%
20D
-3.38%
$209.78
Act: +6.58%
abbv-202602040001551152false00015511522026-02-042026-02-040001551152us-gaap:CommonStockMemberexch:XNYS2026-02-042026-02-040001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2026-02-042026-02-040001551152abbv:Sec1250SeniorNotesDue2031Memberexch:XNYS2026-02-042026-02-04
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 4, 2026
(Exact name of registrant as specified in its charter) Delaware 001-35565 32-0375147 (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On February 4, 2026, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Exhibit 99.1 Press Release dated February 4, 2026 (furnished pursuant to Item 2.02).
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:February 4, 2026By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Jan 7, 2026 · 100% conf.
1D
-1.57%
$213.70
Act: +0.73%
5D
-3.49%
$209.54
Act: +1.70%
20D
-3.38%
$209.78
Act: +6.58%
abbv-202601070001551152false00015511522026-01-072026-01-070001551152us-gaap:CommonStockMemberexch:XNYS2026-01-072026-01-070001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2026-01-072026-01-070001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2026-01-072026-01-070001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2026-01-072026-01-070001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2026-01-072026-01-070001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2026-01-072026-01-07
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 7, 2026
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas
0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2025 are expected to include acquired IPR&D and milestones expense of $1.3 billion on a pre-tax basis, representing an unfavorable impact of $0.71 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended December 31, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.
While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on October 31, 2025 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2025. AbbVie’s full-year 2025 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2025 acquired IPR&D and milestones expense, is $9.90 - $9.94. AbbVie’s fourth quarter 2025 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2025 acquired IPR&D and milestones expense, is $2.61 - $2.65.
Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2025 including the estimated acquired IPR&D and milestones expense incurred during the fourth quarter of 2025.
The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbVie Inc. under the Exchange Act or under the Securities Act of 1933, as a
Oct 31, 2025
abbv-202510310001551152false00015511522025-10-312025-10-310001551152us-gaap:CommonStockMemberexch:XNYS2025-10-312025-10-310001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2025-10-312025-10-310001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2025-10-312025-10-31
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 31, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On October 31, 2025, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Exhibit 99.1 Press Release dated October 31, 2025 (furnished pursuant to Item 2.02).
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:October 31, 2025By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Oct 3, 2025
abbv-202510030001551152false00015511522025-10-032025-10-030001551152us-gaap:CommonStockMemberexch:XNYS2025-10-032025-10-030001551152us-gaap:CommonStockMemberexch:XCHI2025-10-032025-10-030001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2025-10-032025-10-030001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2025-10-032025-10-030001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2025-10-032025-10-030001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2025-10-032025-10-030001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2025-10-032025-10-03
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 3, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2025 are expected to include acquired IPR&D and milestones expense of $2.7 billion on a pre-tax basis, representing an unfavorable impact of $1.50 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended September 30, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.
While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on July 31, 2025 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2025. AbbVie’s full-year 2025 adjusted diluted earnings per share guidance range, including the impact of third quarter 2025 acquired IPR&D and milestones expense, is $10.38 - $10.58. AbbVie’s third quarter 2025 adjusted diluted earnings per share guidance range, including the impact of third quarter 2025 acquired IPR&D and milestones expense, is $1.74 - $1.78.
Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2025 including the estimated acquired IPR&D and milestones expense incurred during the third quarter of 2025.
The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbVie Inc. under
Jul 31, 2025
abbv-202507310001551152false00015511522025-07-312025-07-310001551152us-gaap:CommonStockMemberexch:XNYS2025-07-312025-07-310001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2025-07-312025-07-310001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2025-07-312025-07-310001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2025-07-312025-07-310001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2025-07-312025-07-310001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2025-07-312025-07-31
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 31, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On July 31, 2025, AbbVie Inc. issued a press release announcing financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Exhibit 99.1 Press Release dated July 31, 2025 (furnished pursuant to Item 2.02).
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:July 31, 2025By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Jul 3, 2025
abbv-202507030001551152false00015511522025-07-032025-07-030001551152us-gaap:CommonStockMemberexch:XNYS2025-07-032025-07-030001551152us-gaap:CommonStockMemberexch:XCHI2025-07-032025-07-030001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2025-07-032025-07-030001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2025-07-032025-07-030001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2025-07-032025-07-030001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2025-07-032025-07-030001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2025-07-032025-07-03
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 3, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2025 are expected to include acquired IPR&D and milestones expense of $823 million on a pre-tax basis, representing an unfavorable impact of $0.42 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.
While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on April 25, 2025 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the first quarter of 2025. AbbVie’s full-year 2025 adjusted diluted earnings per share guidance range, including the impact of second quarter 2025 acquired IPR&D and milestones expense, is $11.67 - $11.87. AbbVie’s second quarter 2025 adjusted diluted earnings per share guidance range, including the impact of second quarter 2025 acquired IPR&D and milestones expense, is $2.84 - $2.88.
Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2025 including the estimated acquired IPR&D and milestones expense incurred during the second quarter of 2025.
The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbVie Inc. under th
Apr 25, 2025
abbv-202504250001551152false00015511522025-04-252025-04-250001551152exch:XNYSus-gaap:CommonStockMember2025-04-252025-04-250001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2025-04-252025-04-250001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2025-04-252025-04-250001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2025-04-252025-04-250001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2025-04-252025-04-250001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2025-04-252025-04-25
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 25, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange NYSE Texas
0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On April 25, 2025, AbbVie Inc. issued a press release announcing financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Exhibit 99.1 Press Release dated April 25, 2025 (furnished pursuant to Item 2.02).
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:April 25, 2025By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Apr 3, 2025
abbv-202504030001551152false00015511522025-04-032025-04-030001551152exch:XCHIus-gaap:CommonStockMember2025-04-032025-04-030001551152exch:XNYSus-gaap:CommonStockMember2025-04-032025-04-030001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2025-04-032025-04-030001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2025-04-032025-04-030001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2025-04-032025-04-030001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2025-04-032025-04-030001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2025-04-032025-04-03
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 3, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange
0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are expected to include acquired IPR&D and milestones expense of $248 million on a pre-tax basis, representing an unfavorable impact of $0.13 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.
While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on January 31, 2025 excluded the impact of acquired IPR&D and milestones expense that may be incurred in 2025. AbbVie’s full-year 2025 adjusted diluted earnings per share guidance range, including the impact of first quarter 2025 acquired IPR&D and milestones expense, is $11.99 - $12.19. AbbVie’s first quarter 2025 adjusted diluted earnings per share guidance range, including the impact of first quarter 2025 acquired IPR&D and milestones expense, is $2.34 - $2.38. This guidance does not reflect the impact related to AbbVie and Gubra’s licensing agreement to develop GUB014295, as that transaction closed after the first quarter of 2025.
Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2025 including the estimated acquired IPR&D and milestones expense incurred during the first quarter of 2025.
The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as ame
Jan 31, 2025
abbv-202501310001551152false00015511522025-01-312025-01-310001551152exch:XCHIus-gaap:CommonStockMember2025-01-312025-01-310001551152exch:XNYSus-gaap:CommonStockMember2025-01-312025-01-310001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2025-01-312025-01-310001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2025-01-312025-01-310001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2025-01-312025-01-310001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2025-01-312025-01-310001551152exch:XNYSabbv:Sec1250SeniorNotesDue2031Member2025-01-312025-01-31
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 31, 2025
(Exact name of registrant as specified in its charter) Delaware 001-35565 32-0375147 (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On January 31, 2025, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Exhibit 99.1 Press Release dated January 31, 2025 (furnished pursuant to Item 2.02).
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:January 31, 2025By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Jan 6, 2025
abbv-202501060001551152false00015511522025-01-062025-01-060001551152exch:XNYSus-gaap:CommonStockMember2025-01-062025-01-060001551152exch:XCHIus-gaap:CommonStockMember2025-01-062025-01-060001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2025-01-062025-01-060001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2025-01-062025-01-060001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2025-01-062025-01-060001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2025-01-062025-01-060001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2025-01-062025-01-06
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 6, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange
0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2024 are expected to include acquired IPR&D and milestones expense of $1.6 billion on a pre-tax basis, representing an unfavorable impact of $0.88 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended December 31, 2024 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.
While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2024 previously announced on October 30, 2024 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2024. AbbVie’s full-year 2024 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2024 acquired IPR&D and milestones expense, is $10.02 - $10.06. AbbVie’s fourth quarter 2024 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2024 acquired IPR&D and milestones expense, is $2.06 - $2.10.
Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2024 including the estimated acquired IPR&D and milestones expense incurred during the fourth quarter of 2024.
The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings b
Oct 30, 2024
abbv-202410300001551152false00015511522024-10-302024-10-300001551152exch:XNYSus-gaap:CommonStockMember2024-10-302024-10-300001551152exch:XCHIus-gaap:CommonStockMember2024-10-302024-10-300001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2024-10-302024-10-300001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2024-10-302024-10-300001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2024-10-302024-10-300001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-10-302024-10-300001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2024-10-302024-10-30
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 2024
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange
0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On October 30, 2024, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Exhibit 99.1 Press Release dated October 30, 2024 (furnished pursuant to Item 2.02).
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:October 30, 2024By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Oct 3, 2024
abbv-202410030001551152false00015511522024-10-032024-10-030001551152exch:XNYSus-gaap:CommonStockMember2024-10-032024-10-030001551152exch:XCHIus-gaap:CommonStockMember2024-10-032024-10-030001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2024-10-032024-10-030001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2024-10-032024-10-030001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2024-10-032024-10-030001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-10-032024-10-030001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2024-10-032024-10-03
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 3, 2024
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange
0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2024 are expected to include acquired IPR&D and milestones expense of $82 million on a pre-tax basis, representing an unfavorable impact of $0.04 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended September 30, 2024 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.
While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2024 previously announced on August 1, 2024 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2024. AbbVie’s full-year 2024 adjusted diluted earnings per share guidance range, including the impact of third quarter 2024 acquired IPR&D and milestones expense, is $10.67 - $10.87. AbbVie’s third quarter 2024 adjusted diluted earnings per share guidance range, including the impact of third quarter 2024 acquired IPR&D and milestones expense, is $2.88 - $2.92.
Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2024 including the estimated acquired IPR&D and milestones expense incurred during the third quarter of 2024.
The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbV
Jul 25, 2024
abbv-202407250001551152false00015511522024-07-252024-07-250001551152exch:XCHIus-gaap:CommonStockMember2024-07-252024-07-250001551152us-gaap:CommonStockMemberexch:XNYS2024-07-252024-07-250001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2024-07-252024-07-250001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2024-07-252024-07-250001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2024-07-252024-07-250001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2024-07-252024-07-250001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2024-07-252024-07-25
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 25, 2024
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange
0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On July 25, 2024, AbbVie Inc. issued a press release announcing financial results for the second quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Exhibit 99.1 Press Release dated July 25, 2024 (furnished pursuant to Item 2.02).
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:July 25, 2024By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Jul 3, 2024
abbv-202407030001551152false00015511522024-07-032024-07-030001551152us-gaap:CommonStockMemberexch:XCHI2024-07-032024-07-030001551152us-gaap:CommonStockMemberexch:XNYS2024-07-032024-07-030001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2024-07-032024-07-030001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2024-07-032024-07-030001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2024-07-032024-07-030001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-07-032024-07-030001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2024-07-032024-07-03
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 3, 2024
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange
0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2024 are expected to include acquired IPR&D and milestones expense of $937 million on a pre-tax basis, representing an unfavorable impact of $0.52 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2024 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.
While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2024 previously announced on April 26, 2024 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the first quarter of 2024. AbbVie’s full-year 2024 adjusted diluted earnings per share guidance range, including the impact of second quarter 2024 acquired IPR&D and milestones expense, is $10.61 - $10.81. AbbVie’s second quarter 2024 adjusted diluted earnings per share guidance range, including the impact of second quarter 2024 acquired IPR&D and milestones expense, is $2.53 - $2.57.
Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2024 including the estimated acquired IPR&D and milestones expense incurred during the second quarter of 2024.
The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbVie
Apr 26, 2024
abbv-202404260001551152false00015511522024-04-262024-04-260001551152us-gaap:CommonStockMemberexch:XNYS2024-04-262024-04-260001551152exch:XCHIus-gaap:CommonStockMember2024-04-262024-04-260001551152abbv:Sec1.375SeniorNotesDue2024Memberexch:XNYS2024-04-262024-04-260001551152exch:XNYSabbv:Sec1250SeniorNotesDue2024Member2024-04-262024-04-260001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2024-04-262024-04-260001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2024-04-262024-04-260001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2024-04-262024-04-260001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-04-262024-04-260001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2024-04-262024-04-26
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 26, 2024
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange
1.375% Senior Notes due 2024ABBV24New York Stock Exchange 1.250% Senior Notes due 2024ABBV24BNew York Stock Exchange 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On April 26, 2024, AbbVie Inc. issued a press release announcing financial results for the first quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Exhibit 99.1 Press Release dated April 26, 2024 (furnished pursuant to Item 2.02).
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:April 26, 2024By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Apr 3, 2024
abbv-202404030001551152false00015511522024-04-032024-04-030001551152us-gaap:CommonStockMemberexch:XCHI2024-04-032024-04-030001551152us-gaap:CommonStockMemberexch:XNYS2024-04-032024-04-030001551152exch:XNYSabbv:Sec1.375SeniorNotesDue2024Member2024-04-032024-04-030001551152abbv:Sec1250SeniorNotesDue2024Memberexch:XNYS2024-04-032024-04-030001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2024-04-032024-04-030001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2024-04-032024-04-030001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2024-04-032024-04-030001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-04-032024-04-030001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2024-04-032024-04-03
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 3, 2024
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange
1.375% Senior Notes due 2024ABBV24New York Stock Exchange 1.250% Senior Notes due 2024ABBV24BNew York Stock Exchange 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
Reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2024 are expected to include acquired IPR&D and milestones expense of $164 million on a pre-tax basis, representing an unfavorable impact of $0.08 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended March 31, 2024 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.
While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2024 previously announced on February 12, 2024 excluded the impact of acquired IPR&D and milestones expense that may be incurred in 2024. AbbVie’s full-year 2024 adjusted diluted earnings per share guidance range, including the impact of first quarter 2024 acquired IPR&D and milestones expense, is $10.97 - $11.17. AbbVie’s first quarter 2024 adjusted diluted earnings per share guidance range, including the impact of first quarter 2024 acquired IPR&D and milestones expense, is $2.18 - $2.22.
Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2024 including the estimated acquired IPR&D and milestones expense incurred during the first quarter of 2024.
The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not
Feb 2, 2024
abbv-202402020001551152false00015511522024-02-022024-02-020001551152exch:XCHIus-gaap:CommonStockMember2024-02-022024-02-020001551152exch:XNYSus-gaap:CommonStockMember2024-02-022024-02-020001551152abbv:Sec1.375SeniorNotesDue2024Memberexch:XNYS2024-02-022024-02-020001551152exch:XNYSabbv:Sec1250SeniorNotesDue2024Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec2625SeniorNotesDue2028Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-02-022024-02-020001551152exch:XNYSabbv:Sec1250SeniorNotesDue2031Member2024-02-022024-02-02
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 2, 2024
(Exact name of registrant as specified in its charter) Delaware 001-35565 32-0375147 (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange 1.375% Senior Notes due 2024ABBV24New York Stock Exchange 1.250% Senior Notes due 2024ABBV24BNew York Stock Exchange 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On February 2, 2024, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Exhibit 99.1 Press Release dated February 2, 2024 (furnished pursuant to Item 2.02).
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:February 2, 2024By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Jan 5, 2024
abbv-202401050001551152false00015511522024-01-052024-01-050001551152exch:XNYSus-gaap:CommonStockMember2024-01-052024-01-050001551152exch:XCHIus-gaap:CommonStockMember2024-01-052024-01-050001551152exch:XNYSabbv:Sec1.375SeniorNotesDue2024Member2024-01-052024-01-050001551152exch:XNYSabbv:Sec1250SeniorNotesDue2024Member2024-01-052024-01-050001551152exch:XNYSabbv:Sec0.750SeniorNotesDue2027Member2024-01-052024-01-050001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2024-01-052024-01-050001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2024-01-052024-01-050001551152exch:XNYSabbv:Sec2125SeniorNotesDue2029Member2024-01-052024-01-050001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2024-01-052024-01-05
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 5, 2024
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange
1.375% Senior Notes due 2024ABBV24New York Stock Exchange 1.250% Senior Notes due 2024ABBV24BNew York Stock Exchange 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2023 are expected to include acquired IPR&D and milestones expense of $282 million on a pre-tax basis, representing an unfavorable impact of $0.15 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended December 31, 2023 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.
While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2023 previously announced on October 27, 2023 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2023. AbbVie’s full-year 2023 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2023 acquired IPR&D and milestones expense, is $11.04 - $11.08. AbbVie’s fourth quarter 2023 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2023 acquired IPR&D and milestones expense, is $2.72 - $2.76.
Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2023 including the estimated acquired IPR&D and milestones expense incurred during the fourth quarter of 2023.
The information set forth in this Current Report on Form 8-K,
Oct 27, 2023
abbv-202310270001551152false00015511522023-10-272023-10-270001551152us-gaap:CommonStockMemberexch:XNYS2023-10-272023-10-270001551152us-gaap:CommonStockMemberexch:XCHI2023-10-272023-10-270001551152exch:XNYSabbv:Sec1500SeniorNotesDue2023Member2023-10-272023-10-270001551152abbv:Sec1.375SeniorNotesDue2024Memberexch:XNYS2023-10-272023-10-270001551152exch:XNYSabbv:Sec1250SeniorNotesDue2024Member2023-10-272023-10-270001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2023-10-272023-10-270001551152exch:XNYSabbv:Sec2.125SeniorNotesdue2028Member2023-10-272023-10-270001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2023-10-272023-10-270001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2023-10-272023-10-270001551152exch:XNYSabbv:Sec1.250SeniorNotesdue2031Member2023-10-272023-10-27
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 27, 2023
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange
1.500% Senior Notes due 2023ABBV23BNew York Stock Exchange 1.375% Senior Notes due 2024ABBV24New York Stock Exchange 1.250% Senior Notes due 2024ABBV24BNew York Stock Exchange 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On October 27, 2023, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Exhibit 99.1 Press Release dated October 27, 2023 (furnished pursuant to Item 2.02).
104The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:October 27, 2023By:/s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer
Oct 4, 2023
abbv-202310040001551152false00015511522023-10-042023-10-040001551152us-gaap:CommonStockMemberexch:XCHI2023-10-042023-10-040001551152us-gaap:CommonStockMemberexch:XNYS2023-10-042023-10-040001551152abbv:Sec1500SeniorNotesDue2023Memberexch:XNYS2023-10-042023-10-040001551152abbv:Sec1.375SeniorNotesDue2024Memberexch:XNYS2023-10-042023-10-040001551152abbv:Sec1250SeniorNotesDue2024Memberexch:XNYS2023-10-042023-10-040001551152abbv:Sec0.750SeniorNotesDue2027Memberexch:XNYS2023-10-042023-10-040001551152abbv:Sec2.125SeniorNotesdue2028Memberexch:XNYS2023-10-042023-10-040001551152abbv:Sec2625SeniorNotesDue2028Memberexch:XNYS2023-10-042023-10-040001551152abbv:Sec2125SeniorNotesDue2029Memberexch:XNYS2023-10-042023-10-040001551152abbv:Sec1.250SeniorNotesdue2031Memberexch:XNYS2023-10-042023-10-04
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 4, 2023
(Exact name of registrant as specified in its charter)
Delaware 001-35565 32-0375147 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 North Waukegan Road North Chicago, Illinois 60064-6400 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange Chicago Stock Exchange
1.500% Senior Notes due 2023ABBV23BNew York Stock Exchange 1.375% Senior Notes due 2024ABBV24New York Stock Exchange 1.250% Senior Notes due 2024ABBV24BNew York Stock Exchange 0.750% Senior Notes due 2027ABBV27New York Stock Exchange 2.125% Senior Notes due 2028ABBV28New York Stock Exchange 2.625% Senior Notes due 2028ABBV28BNew York Stock Exchange 2.125% Senior Notes due 2029ABBV29New York Stock Exchange 1.250% Senior Notes due 2031ABBV31New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2023 are expected to include acquired IPR&D and milestones expense of $66 million on a pre-tax basis, representing an unfavorable impact of $0.04 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended September 30, 2023 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.
While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2023 previously announced on July 27, 2023 excluded the impact of acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2023. AbbVie’s full-year 2023 adjusted diluted earnings per share guidance range, including the impact of third quarter 2023 acquired IPR&D and milestones expense, is $10.86 - $11.06. AbbVie’s third quarter 2023 adjusted diluted earnings per share guidance range, including the impact of third quarter 2023 acquired IPR&D and milestones expense, is $2.76 - $2.86.
Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2023 including the estimated acquired IPR&D a
This page provides AbbVie Inc. (ABBV) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on ABBV's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.